Secarna Pharmaceuticals announces the acquisition of LNAplus(TM) based antisense drug candidates by Lipigon Pharmaceuticals
Secarna and Lipigon jointly generated candidates for cardiovascular and metabolic diseases in a target validation and drug discovery collaboration Lipigon...
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities